I really just wanted to be cured so I could fly.
In New Orleans, a 23-year-old man has become the first person in Louisiana to receive FDA-approved gene editing therapy for sickle cell disease — a condition that has shaped his body, limited his horizons, and driven him toward a singular dream: to fly. The treatment, which reactivates the protective fetal hemoglobin silenced by the disease, represents not merely a medical milestone but a reckoning with what it means to rewrite the story one's own biology has been telling since birth. Louisiana, which bears one of the heaviest sickle cell burdens in the nation, now stands at the threshold of a new chapter — one patient, one harvested stem cell, one distant laboratory in Scotland at a time.
- A disease that quietly announces itself in infancy has spent decades sending thousands of Louisianans into emergency rooms with pain so severe it defies ordinary description.
- A single treatment costing up to $3.1 million required 18 months of insurance negotiations just to reach the starting line — exposing the vast distance between medical possibility and medical access.
- Stem cells harvested in New Orleans, rewritten in Scotland, and returned frozen at minus 180 degrees were delivered in two minutes through a chest tube — the anticlimactic pivot point of an 18-month ordeal.
- The patient now waits at home under isolation orders while an entirely new blood system slowly assembles itself inside him, cell by dividing cell.
- A 14-year-old from Monroe is already next in the pipeline, and the first patient has begun building a community for others who might one day follow him into the sky.
Daniel Cressy left Manning Family Children's Hospital in New Orleans this week after months of isolation, carrying the distinction of being Louisiana's first patient to receive FDA-approved gene editing therapy for sickle cell disease. At 23, he had spent his life subject to the disease's defining cruelty: blood cells warped into crescent shapes that clot in joints and organs, triggering pain that sends patients to emergency rooms again and again. Louisiana ranks among the highest states in the nation for sickle cell prevalence, with roughly 80 new diagnoses each year and more than 1,400 hospitalizations in 2023 alone.
Cressy's path to treatment began with a rejection letter from the FAA. He had applied for a pilot's license and been denied because of his condition. When he learned that Manning Family Children's had become a treatment center for gene therapies, he contacted Dr. Benjamin Watkins, a pediatric hematologist-oncologist who had watched early clinical trials show a 97 percent success rate in reducing pain. Cressy was first in line. Eighteen months of insurance negotiations followed — the therapy costs between $2.2 million and $3.1 million — before treatment could begin.
His stem cells were harvested and sent to a genetics laboratory in Scotland, where technicians rewrote his genetic instructions to reactivate the fetal hemoglobin that had protected him before the disease took hold. Back in New Orleans, four days of chemotherapy cleared the sickled cells from his body. The edited cells returned from Scotland frozen at minus 180 degrees Fahrenheit and were delivered through a tube in his chest in under two minutes. Then came the waiting — four weeks of isolation while the new cells found their way to his bone marrow, multiplied, and slowly built an entirely new blood system.
Cressy went home this week, still under monitoring, but with the FAA's confirmation that other gene therapy patients have already obtained pilot's licenses. He has befriended one of them and launched a brand called 'Privileged Pilots,' speaking at aviation and sickle cell events about what the treatment makes possible. Next week, a 14-year-old from Monroe will begin stem cell harvesting as the second patient in the pipeline. Cressy waits out his isolation with his eyes, as ever, on the sky.
Daniel Cressy walked out of Manning Family Children's Hospital in New Orleans this week after months of isolation, carrying with him the weight of being first. At 23, he is Louisiana's first patient to receive FDA-approved gene editing therapy for sickle cell disease—a treatment that rewrites the genetic instructions his body has been following since infancy, when a faulty hemoglobin gene switched on and began warping his blood cells into the crescent shapes that cause the disease's signature agony.
Sickle cell disease announces itself quietly. Babies born with it often look perfectly healthy at first, their bodies still relying on fetal hemoglobin produced in the womb—a protective protein that works. But weeks or months after birth, the genetic switch flips. The mutation takes over. Blood cells stiffen and curve, clotting easily, jamming in joints and organs, triggering pain so severe it sends patients to emergency rooms repeatedly throughout their lives. In Louisiana alone, roughly 80 babies receive this diagnosis each year. The state ranks among the highest in the nation for sickle cell prevalence per capita. In 2023, 1,430 people were hospitalized with the disease. Medicaid covers about 3,000 patients, though the true number living with the condition remains unknown.
Cressy's motivation for seeking treatment was specific and urgent: he wanted to fly. The Federal Aviation Administration had denied his application for a pilot's license because of his condition. When he learned that Manning Family Children's had become a treatment center for gene therapies in March 2024, he contacted Dr. Benjamin Watkins, a pediatric hematologist-oncologist who had come to the hospital three years earlier after witnessing early clinical trials at Emory University. Those trials showed a 97 percent success rate in reducing pain. Cressy was first in line. "I really just wanted to be cured so I could fly," he said. Once he realized he would be the first patient in Louisiana to undergo the procedure, he decided to document the experience. "I figured I should share what it's actually like so other patients know it's possible."
The path to treatment took 18 months of coordination with Louisiana insurers to cover the staggering cost—between $2.2 million and $3.1 million depending on which therapy was used, not including hospital stays, chemotherapy, and other expenses. The treatment is reserved for patients with the most severe forms of the disease, those older than 12 who have experienced at least two vaso-occlusive events in the past year—the excruciating episodes that drive emergency department visits. Cressy qualified.
In August and September, his stem cells were harvested and sent to a genetics laboratory in Scotland, where technicians rewrote his genetic code. Unlike some gene therapies that correct the sickle cell mutation itself, Cressy's treatment reverted his genes backward, reactivating the fetal hemoglobin that had protected him before the disease switched on. In early March, he underwent four days of chemotherapy to clear the sickled cells from his body, making room for the new ones. The edited cells arrived from Scotland frozen at minus 180 degrees Fahrenheit. A technician thawed them, transferred them to a syringe, and delivered them through a tube in his chest. "It's the easiest part of the process," Watkins said. "It takes two minutes."
What followed was a waiting game measured in weeks. Within 24 hours, the genetically edited cells found their way to Cressy's bone marrow. Then they had to multiply, divide, and replicate—what Watkins called "great-great-great-grandmother cells" that would spawn an entirely new blood system. The process takes about four weeks for the new cells to mature enough to enter the bloodstream. During that time, Cressy remained isolated in the hospital, given medication to manage pain and prevent infection while his fragile new immune system developed. "It's kind of like having a newborn," Watkins said. The chemotherapy side effects—hair loss, nausea, mouth sores—would fade as the stem cells grew and began healing him.
This week, Cressy went home, still under strict isolation orders and continuous monitoring. The FAA had already confirmed to him that other sickle cell patients who underwent gene therapy were able to obtain pilot's licenses and fly. He has befriended one of them and started a brand called "Privileged Pilots," speaking at aviation and sickle cell events about what the treatment makes possible. Next week, Manning Family Children's will begin harvesting stem cells from a 14-year-old from Monroe, the second patient in the pipeline. For now, Cressy waits for his isolation period to end, his eyes still on the sky.
Notable Quotes
I really just wanted to be cured so I could fly.— Daniel Cressy, on his motivation for seeking gene therapy
It's kind of like having a newborn. And the side effects of having chemotherapy—hair loss, nausea, mouth sores—gets better as these stem cells grow then start to heal him.— Dr. Benjamin Watkins, describing the recovery process
The Hearth Conversation Another angle on the story
Why does sickle cell disease hit Louisiana so hard compared to other states?
The disease is rooted in ancestry—it's most common in people with African heritage, where the sickle cell trait once offered protection against malaria. Louisiana's demographics mean a higher concentration of people carrying the gene. About 80 babies are diagnosed here every year, and we're still building a registry to understand the full scope.
So Cressy's treatment doesn't actually fix the mutation—it just turns the clock back?
Exactly. His cells are rewritten to produce fetal hemoglobin again, the protein that protected him before the disease switched on. It's not correcting the defect; it's bypassing it entirely. The body forgets it ever had sickle cell.
And the isolation afterward—that's because his immune system is basically brand new?
Right. After chemotherapy wipes out his old blood cells, his body has to rebuild everything from scratch using the edited stem cells. For weeks, he's vulnerable to any infection. It's like having a newborn's immune system in an adult body.
What happens to the damage already done—the pain, the scarring in his organs?
That's the hard part. The therapy can only prevent future damage. Years of sickle cell pain and complications leave marks the treatment can't erase. But stopping it from getting worse is still transformative for someone like Cressy.
Why is the pilot's license so important to him specifically?
It's concrete. It's something the disease took from him that he can now pursue. The FAA had denied him because of the unpredictability and pain. Now that he's been treated, other patients have already gotten their licenses. For Cressy, it's proof the cure works—not just in blood counts, but in the life you can actually live.
What's the barrier for other patients who might want this?
Cost, mainly. Two to three million dollars before you even count the hospital stay. And you have to meet strict criteria—severe disease, multiple pain crises in the past year, old enough to handle the chemotherapy. It's not available to everyone with sickle cell, only those suffering the most.